Nuevolution AB (NUE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nuevolution AB (NUE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9386
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nuevolution AB (Nuevolution) is a biopharmaceutical company focused on developing drug treatments for cancer and chronic inflammatory diseases. The company’s pipeline products include RORyt inhibitor, BRD (BD1), cytokine X, RORyt agonist, and GRP78. Its products are used for various indications such as dermatology, psoriatic arthritis, inflammation, immune-oncology, and oncology. Nuevolution also develops Chemetics, a patent protected drug discovery platform that enables the discovery of novel small molecule tablet based drug candidates and provides access to screening of billions of molecules and optimization of drug properties in the process of identifying the drug candidate. The company partners with other pharma and biotech companies for its drug discovery and development. Nuevolution is headquartered in Copenhagen, Denmark.

Nuevolution AB (NUE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nuevolution AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nuevolution AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution AB, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nuevolution Raises US$13.7 Million Venture Financing Round 11
Partnerships 12
Nuevolution Enters into Co-Development Agreement with Almirall 12
Nuevolution Enters into Research Agreement with Amgen 13
Nuevolution Enters into Discovery Agreement with Janssen Biotech 14
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 15
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 17
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 18
Licensing Agreements 19
Amgen Exercises Option for Licensing Agreement with Nuevolution 19
Janssen Biotech Enters into Licensing Agreement with Nuevolution 20
Nuevolution Enters Into Licensing Agreement With Novartis 21
Equity Offering 22
Nuevolution Raises USD290 Million in IPO of Shares 22
Nuevolution AB – Key Competitors 23
Nuevolution AB – Key Employees 24
Nuevolution AB – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
May 08, 2018: Nuevolution announces its results for the first quarter of 2018 and provides update on partnership discussions 26
Feb 08, 2018: Nuevolution announces its year-end report for 2017 and report for the three-month period ended 31 December 2017 27
Sep 06, 2017: Nuevolution announces its results for the fourth quarter and full year 2016/17 28
May 17, 2017: Nuevolution announces its results for the third quarter 2016/17 29
Corporate Communications 30
Apr 24, 2018: Nuevolution’s Board of Directors to Be Reduced From Six to Five Members 30
Jan 23, 2018: Nuevolution appoint Dr. Paul Scigalla as Chief Medical Officer on consultancy basis 31
Oct 30, 2017: Fredrik Arp is Proposed as Board Member in Nuevolution 32
Legal and Regulatory 33
Dec 08, 2017: The Danish Eastern High Court revokes the Maritime and Commercial High Court’s decision of 22 February 2016 in favour of Nuevolution’s request 33
Product News 34
08/22/2018: Nuevolution discloses the identity of its Cytokine X program being interleukin IL-17A and initiates promotion of its small molecule IL-17A inhibitor program targeting inflammatory diseases 34
May 17, 2018: Nuevolution announces the publication of a second scientific article from the collaboration with Nobel Laureate Dr. Robert J. Lefkowitz 35
Feb 14, 2017: Nuevolution Technology Progress: Nuevolution Scales its Compound Collection to 40 Trillion Using its Chemetics Drug Discovery Platform 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Nuevolution AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nuevolution AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nuevolution AB, Deals By Therapy Area, 2012 to YTD 2018 9
Nuevolution AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution Raises US$13.7 Million Venture Financing Round 11
Nuevolution Enters into Co-Development Agreement with Almirall 12
Nuevolution Enters into Research Agreement with Amgen 13
Nuevolution Enters into Discovery Agreement with Janssen Biotech 14
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 15
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 17
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 18
Amgen Exercises Option for Licensing Agreement with Nuevolution 19
Janssen Biotech Enters into Licensing Agreement with Nuevolution 20
Nuevolution Enters Into Licensing Agreement With Novartis 21
Nuevolution Raises USD290 Million in IPO of Shares 22
Nuevolution AB, Key Competitors 23
Nuevolution AB, Key Employees 24
Nuevolution AB, Subsidiaries 25

List of Figures
Nuevolution AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nuevolution AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nuevolution AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Nuevolution AB (NUE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wright Medical Group NV (WMGI):医療機器:M&Aディール及び事業提携情報
    Summary Wright Medical Group NV (Wright) is a medical device company which focuses on extremity and biologic solutions. The company designs, manufactures and markets reconstructive joint devices including extremity implants for the shoulder, elbow, foot, ankle and hand; foot and ankle products. It a …
  • Murree Brewery Co. Ltd.:戦略・SWOT・企業財務分析
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Homology Medicines, Inc. (FIXX):製薬・医療:M&Aディール及び事業提携情報
    Summary Homology Medicines, Inc. (Homology Medicines) is a pre-clinical stage biopharmaceutical company engaged in translating gene editing and gene therapy into novel treatment for patients suffering from rare genetic diseases. It offers HMI-102 product, which is in clinical stage for the treatment …
  • PQ Group Holdings Inc (PQG):企業の財務・戦略的SWOT分析
    PQ Group Holdings Inc (PQG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • CDW Corporation:戦略・SWOT・企業財務分析
    CDW Corporation - Strategy, SWOT and Corporate Finance Report Summary CDW Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SFS Group AG:企業の戦略・SWOT・財務情報
    SFS Group AG - Strategy, SWOT and Corporate Finance Report Summary SFS Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Caris Life Sciences Inc:企業の製品パイプライン分析
    Summary Caris Life Sciences Inc (Caris Life) is a biotechnology company. The company’s molecular scientific offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make personalized treatment decisions. Its ADAPT biotargeting system, is a plat …
  • Ergon Inc:企業の戦略的SWOT分析
    Ergon Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Enterprise Ireland:医療機器:M&Aディール及び事業提携情報
    Summary Enterprise Ireland (EI) is an economic development organization that offers enterprise development programs. The organization’s activities include funding supports, export assistance, supports to develop competitiveness, incentives to stimulate in-company research and development, assistance …
  • Sernova Corp (SVA):製薬・医療:M&Aディール及び事業提携情報
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like …
  • Orbit International Corp.:企業の戦略・SWOT・財務情報
    Orbit International Corp. - Strategy, SWOT and Corporate Finance Report Summary Orbit International Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Thermalin Diabetes LLC-製薬・医療分野:企業M&A・提携分析
    Summary Thermalin Diabetes LLC (Thermalin) is an insulin analogs developer. The company develops concentrated insulin analog for the treatment of individuals with insulin resistance and for use in miniature insulin pumps. It develops both molecular and formulation strategies to produce an acting ana …
  • GTx Inc (GTXI):製薬・医療:M&Aディール及び事業提携情報
    Summary GTx Inc (GTx) is a biopharmaceutical company that discovers, develops and commercializes novel targeted hormonal therapies. It develops small molecules that targets hormone pathways for the treatment of various cancers including breast and prostate cancer; and other serious medical condition …
  • PT Medco Energi Internasional Tbk (MEDC):電力:M&Aディール及び事業提携情報
    Summary PT Medco Energi Internasional Tbk (MedcoEnergi), a subsidiary of Encore Energy Pte. Ltd., is an integrated energy company. It explores for and develops oil and gas fields. The company provides energy related services such as power production, engineering procurement and construction (EPC), o …
  • Sopheon Plc:企業の戦略・SWOT・財務情報
    Sopheon Plc - Strategy, SWOT and Corporate Finance Report Summary Sopheon Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Groupe Sodiaal:戦略・SWOT・企業財務分析
    Groupe Sodiaal - Strategy, SWOT and Corporate Finance Report Summary Groupe Sodiaal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Infor Global Solutions Inc:企業の戦略的SWOT分析
    Infor Global Solutions Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Technicolor SA:企業の戦略・SWOT・財務情報
    Technicolor SA - Strategy, SWOT and Corporate Finance Report Summary Technicolor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Capstone Therapeutics Corp (CAPS):企業の財務・戦略的SWOT分析
    Summary Capstone Therapeutics Corp (Capstone), formerly OrthoLogic Corp, is a biotechnology company that develops and sells novel peptides and other molecules for helping patients with under-served medical conditions. The company develops Apo E mimetic peptide molecule AEM-28 and its analogs that ha …
  • KBC Group NV:企業の戦略・SWOT・財務情報
    KBC Group NV - Strategy, SWOT and Corporate Finance Report Summary KBC Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆